Clinical Trial

Evaluation of Memantine in the Preservation of Memory and Neurocognition Following CSI

Study acronym: MEMENTO
Recruiting Phase 3
View on ClinicalTrials.gov →
Record status
This record was last updated April 9, 2025 (before its estimated January 2026 completion). Its status may not reflect the trial's current state.
Summary
The goal of this clinical trial is to evaluate the role of memantine in preservation of memory and neurocognition in patients undergoing craniospinal irradiation. Participants will be randomised into two arms and the interventional arm will receive memantine along with the standard treatment. Researchers will compare the neurocognitive tests of participants in both the arms to see if memantine leads to significant preservation of memory and cognition post radiation therapy.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2024-02-16; most recent amendment 2025-04-08.
Status change: Not Yet Recruiting → Recruiting 2024-02-29
Trial Details
NCT Number NCT06275035
Lead Sponsor Tata Memorial Centre
Conditions Neurocognitive Dysfunction
Enrollment 101 participants
Start Date 2024-02-22
Primary Completion 2026-01 (estimated)
Study Completion 2031-01 (estimated)
Updated on ClinicalTrials.gov 2025-04-09